Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.56 |
| ▸ | GSK3B | P49841 | 1/20 | 0.56 |
| ▸ | NAMPT | P43490 | 1/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.49 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.49 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.45 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5921849 | 0.93 | PIK3CA (0.54) | PTPN1GSK3BNAMPTCES2CES1 | |
| SCHEMBL4847457 | 0.89 | PTPN1 (0.63) | PTPN1GSK3BCES2CES1PIK3CA | |
| SCHEMBL6282451 | 0.85 | MAPT (0.51) | MAPTKIF11HDAC1SRD5A2 | |
| SCHEMBL1515765 | 0.84 | MAPT (0.61) | PTPN1GSK3BCES2CES1PIK3CA | |
| SCHEMBL6203734 | 0.83 | ALDH1A1 (0.55) | HIF1APLOD2PLOD3PLOD1MAPT | |
| SCHEMBL2929610 | 0.83 | VNN1 (0.57) | NAMPTCES2POLBSRD5A2 | |
| SCHEMBL11792850 | 0.83 | VNN1 (0.58) | PTPN1GSK3BNAMPTHIF1AEPAS1 | |
| SCHEMBL6339735 | 0.83 | PTPN1 (0.56) | PTPN1GSK3BCES2CES1PIK3CA | |
| SCHEMBL8371456 | 0.83 | PTPN1 (0.56) | PTPN1GSK3BCES2CES1PIK3CA | |
| SCHEMBL2645324 | 0.82 | LTA4H (0.58) | PTPN1NAMPTCES2CES1PLOD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220227735-A1 | THERAPEUTIC METHODS AND COMPOUNDS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2022-07-21 | — | — | US | disclosed |
| WO-2020219591-A1 | THERAPEUTIC METHODS AND COMPOUNDS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-10-29 | — | — | WO | disclosed |
| US-6962933-B1 | Method for inhibiting p38 MAP kinase or TNF-α production using a 1,3-thiazole | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-08 | — | — | US | disclosed |
| US-20050080113-A1 | Medicinal compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-14 | — | — | US | disclosed |
| US-20040097555-A1 | Concomitant drugs | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1402900-A1 | MEDICINAL COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| EP-1027050-B1 | 1,3-THIAZOLES AS ADENOSINE A3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ALLERGY, ASTHMA AND DIABETES | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2004-01-14 | — | — | EP | disclosed |
| EP-1354603-A1 | CONCOMITANT DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2003-10-22 | — | — | EP | disclosed |
| US-6620825-B1 | 1,3-Azole compound substituted by pyridyl; administering as antiasthmatic, antiinflammatory or antiallergen agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-09-16 | — | — | US | disclosed |
| US-6436966-B1 | Adenosine A3 receptor antagonists | TAKEDA CHEMICAL IND., LTD. (JP) | 2002-08-20 | — | — | US | disclosed |
| EP-1205478-A1 | p38MAP KINASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2002-05-15 | — | — | EP | disclosed |
| EP-1027050-A2 | ADENOSINE A3 RECEPTOR ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999021555-A2 | ADENOSINE A3 RECEPTOR ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080113-A1 | Medicinal compositions | TNF, TRAF6, MMP8 | PTPN1 895/4885GSK3B 540/4885NAMPT 1006/4885 |
| US-20040097555-A1 | Concomitant drugs | TNF, CHUK, CNKSR1 | PTPN1 102/4885GSK3B 811/4885NAMPT 1700/4885 |
| US-20220227735-A1 | THERAPEUTIC METHODS AND COMPOUNDS | REN, FURIN, QTRT1 | PTPN1 3471/4885GSK3B 3108/4885NAMPT 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.